Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing a variable disease.

J Kips1

  • 1Department of Respiratory Diseases, Ghent University Hospital, De Pintelaan, B9000 Ghent, Belgium. Johan.kips@rug.ac.be

Pulmonary Pharmacology & Therapeutics
|December 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Numerical validation of a new method to assess aortic pulse wave velocity from a single recording of a brachial artery waveform with an occluding cuff.

Annals of biomedical engineering·2010
Same author

Experimental and numerical modelling of the ventriculosinus shunt (El-Shafei shunt).

Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine·2008
Same author

Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma.

Allergy·2005
Same author

Variation of CD8+ T-lymphocytes around the bronchial internal perimeter in chronic bronchitis.

The European respiratory journal·2003
Same author

Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease.

Histochemistry and cell biology·2001
Same author

The clinical role of long-acting beta2-agonists in COPD.

Respiratory medicine·2000
Same journal

Brain-Derived Neurotrophic Factor (BDNF) Signaling in Respiratory Disease: Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications.

Pulmonary pharmacology & therapeutics·2026
Same journal

PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model.

Pulmonary pharmacology & therapeutics·2026
Same journal

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same journal

TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions.

Pulmonary pharmacology & therapeutics·2026
Same journal

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.

Pulmonary pharmacology & therapeutics·2026
See all related articles

Flexible asthma treatment is key due to symptom variability. Inhaled corticosteroids (ICS) dosing frequency impacts outcomes, with budesonide offering flexibility for managing mild to severe asthma effectively.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Asthma severity fluctuates, necessitating adaptable treatment plans.
  • Inhaled corticosteroids (ICS) are the primary therapy, with dose and frequency being critical factors.
  • Dose-response to ICS varies across asthma indicators.

Purpose of the Study:

  • To evaluate the dose-response relationship of ICS in asthma.
  • To determine optimal dosing strategies for varying asthma severity.
  • To assess the suitability of flexible dosing regimens for asthma management.

Main Methods:

  • Analysis of dose responsiveness of ICS for symptom control and lung function.
  • Comparison of once-daily versus twice-daily budesonide dosing in mild asthma.
  • Evaluation of four-times daily versus twice-daily dosing in moderate-to-severe asthma.

Related Experiment Videos

  • Assessment of a flexible regimen combining low-dose maintenance with high-dose ICS for exacerbations.

    • Main Results:

    • Symptoms and lung function show a flat dose-response curve to low-dose ICS.
    • Prevention of asthma exacerbations demonstrates a more pronounced dose-response.
    • Once-daily budesonide is effective for mild asthma; four-times daily dosing offers maximal benefit in moderate-to-severe asthma.
    • Flexible regimens with ICS are effective for managing asthma exacerbations.

    Conclusions:

    • Flexible dosing strategies are essential for managing variable asthma.
    • Formoterol's pharmacological profile supports flexible dosing in combination inhalers.
    • Single inhaler combination products, like Symbicort, can provide the necessary flexibility for maintenance and reliever therapy in asthma.